GlassScriptPhysician profile
David M Gubernick
NPI 1609259456
$1,650.63
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $570 · 2021: $265 · 2022: $243.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $541.05 | 2019-2022 | |
| Glaxosmithkline, LLC. | $372.05 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $248.12 | 2019-2022 | |
| Genentech USA, INC. | $149.99 | 2019 | |
| Intersect Ent, INC. | $75.82 | 2021 | |
| Genzyme Corporation | $72.99 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.80 | 2020 | |
| Alk-Abello, INC | $65.00 | 2021 | |
| Csl Behring | $43.78 | 2019 | |
| Shire North American Group INC | $13.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gubernick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.